Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease
Shuyao Zhang, Fnu Sidra, Carlos A Alvarez, Mustafa Kinaan, Ildiko Lingvay, Ishak A Mansi · 2024
Read Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease by Shuyao Zhang, Fnu Sidra, Carlos A Alvarez, Mustafa Kinaan, Ildiko Lingvay, Ishak A Mansi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11621321.txt.
Description
Shuyao Zhang and five co-authors emulate a trial of diabetes drugs in veterans with kidney disease. Their 2024 study compares GLP1 receptor agonists with DPP4 inhibitors. The newer drugs may slow kidney decline and heart events. Real-world effects on hospital use and death were unclear.
Records from 2006 to 2021 built the comparison. Over sixteen thousand matched pairs were followed for about two years. The agonist group used acute care less often each year. Deaths from all causes also ran lower. Acute heart events, though, did not differ clearly. Emulated trials can guide practice while true trials catch up.
Catalog record
| CREATOR | Shuyao Zhang, Fnu Sidra, Carlos A Alvarez, Mustafa Kinaan, Ildiko Lingvay, Ishak A Mansi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |